Administrator Verma Statement on FDA’s Biosimilars Action Plan
"CMS congratulates the FDA on the release of the Biosimilars Action Plan. President Trump has set a clear priority to lower drug prices, and the bold steps in this proposal will do just that, while also expanding access for patients. CMS and FDA are both working to accelerate innovation in the biosimilars market – CMS has taken action to do so by providing biosimilars with separate payment codes and by lowering the amount of cost sharing that low-income beneficiaries pay for biosimilars. We look forward to continuing to work with the FDA on the roll-out of the American Patients First blueprint."